FGF23 Actions on Target Tissues—With and Without Klotho

Fibroblast growth factor (FGF) 23 is a phosphaturic hormone whose physiologic actions on target tissues are mediated by FGF receptors (FGFR) and klotho, which functions as a co-receptor that increases the binding affinity of FGF23 for FGFRs. By stimulating FGFR/klotho complexes in the kidney and par...

Full description

Bibliographic Details
Main Authors: Beatrice Richter, Christian Faul
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fendo.2018.00189/full
_version_ 1818339684872355840
author Beatrice Richter
Christian Faul
author_facet Beatrice Richter
Christian Faul
author_sort Beatrice Richter
collection DOAJ
description Fibroblast growth factor (FGF) 23 is a phosphaturic hormone whose physiologic actions on target tissues are mediated by FGF receptors (FGFR) and klotho, which functions as a co-receptor that increases the binding affinity of FGF23 for FGFRs. By stimulating FGFR/klotho complexes in the kidney and parathyroid gland, FGF23 reduces renal phosphate uptake and secretion of parathyroid hormone, respectively, thereby acting as a key regulator of phosphate metabolism. Recently, it has been shown that FGF23 can also target cell types that lack klotho. This unconventional signaling event occurs in an FGFR-dependent manner, but involves other downstream signaling pathways than in “classic” klotho-expressing target organs. It appears that klotho-independent signaling mechanisms are only activated in the presence of high FGF23 concentrations and result in pathologic cellular changes. Therefore, it has been postulated that massive elevations in circulating levels of FGF23, as found in patients with chronic kidney disease, contribute to associated pathologies by targeting cells and tissues that lack klotho. This includes the induction of cardiac hypertrophy and fibrosis, the elevation of inflammatory cytokine expression in the liver, and the inhibition of neutrophil recruitment. Here, we describe the signaling and cellular events that are caused by FGF23 in tissues lacking klotho, and we discuss FGF23’s potential role as a hormone with widespread pathologic actions. Since the soluble form of klotho can function as a circulating co-receptor for FGF23, we also discuss the potential inhibitory effects of soluble klotho on FGF23-mediated signaling which might—at least partially—underlie the pleiotropic tissue-protective functions of klotho.
first_indexed 2024-12-13T15:30:55Z
format Article
id doaj.art-2f3ec7bea76c4d21b7ccfa63e71dfa9d
institution Directory Open Access Journal
issn 1664-2392
language English
last_indexed 2024-12-13T15:30:55Z
publishDate 2018-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj.art-2f3ec7bea76c4d21b7ccfa63e71dfa9d2022-12-21T23:40:11ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922018-05-01910.3389/fendo.2018.00189351823FGF23 Actions on Target Tissues—With and Without KlothoBeatrice RichterChristian FaulFibroblast growth factor (FGF) 23 is a phosphaturic hormone whose physiologic actions on target tissues are mediated by FGF receptors (FGFR) and klotho, which functions as a co-receptor that increases the binding affinity of FGF23 for FGFRs. By stimulating FGFR/klotho complexes in the kidney and parathyroid gland, FGF23 reduces renal phosphate uptake and secretion of parathyroid hormone, respectively, thereby acting as a key regulator of phosphate metabolism. Recently, it has been shown that FGF23 can also target cell types that lack klotho. This unconventional signaling event occurs in an FGFR-dependent manner, but involves other downstream signaling pathways than in “classic” klotho-expressing target organs. It appears that klotho-independent signaling mechanisms are only activated in the presence of high FGF23 concentrations and result in pathologic cellular changes. Therefore, it has been postulated that massive elevations in circulating levels of FGF23, as found in patients with chronic kidney disease, contribute to associated pathologies by targeting cells and tissues that lack klotho. This includes the induction of cardiac hypertrophy and fibrosis, the elevation of inflammatory cytokine expression in the liver, and the inhibition of neutrophil recruitment. Here, we describe the signaling and cellular events that are caused by FGF23 in tissues lacking klotho, and we discuss FGF23’s potential role as a hormone with widespread pathologic actions. Since the soluble form of klotho can function as a circulating co-receptor for FGF23, we also discuss the potential inhibitory effects of soluble klotho on FGF23-mediated signaling which might—at least partially—underlie the pleiotropic tissue-protective functions of klotho.http://journal.frontiersin.org/article/10.3389/fendo.2018.00189/fullFGF23klothofibroblast growth factor receptor 4chronic kidney diseasecardiac hypertrophyinflammation
spellingShingle Beatrice Richter
Christian Faul
FGF23 Actions on Target Tissues—With and Without Klotho
Frontiers in Endocrinology
FGF23
klotho
fibroblast growth factor receptor 4
chronic kidney disease
cardiac hypertrophy
inflammation
title FGF23 Actions on Target Tissues—With and Without Klotho
title_full FGF23 Actions on Target Tissues—With and Without Klotho
title_fullStr FGF23 Actions on Target Tissues—With and Without Klotho
title_full_unstemmed FGF23 Actions on Target Tissues—With and Without Klotho
title_short FGF23 Actions on Target Tissues—With and Without Klotho
title_sort fgf23 actions on target tissues with and without klotho
topic FGF23
klotho
fibroblast growth factor receptor 4
chronic kidney disease
cardiac hypertrophy
inflammation
url http://journal.frontiersin.org/article/10.3389/fendo.2018.00189/full
work_keys_str_mv AT beatricerichter fgf23actionsontargettissueswithandwithoutklotho
AT christianfaul fgf23actionsontargettissueswithandwithoutklotho